Regulatory approach toward vaccines against cancer: the benefit/risk ratio.
Cancer Res
; 36(2 pt 2): 865-6, 1976 Feb.
Article
em En
| MEDLINE
| ID: mdl-1253161
ABSTRACT
Decisions regarding investigational new drug applications for testing of all biologicals to be used in humans, including those designed to prevent or treat cancers, must be considered in terms of benefit/risk ratios. In order for a regulatory organization to make the appropriate decision regarding the testing of new biologicals in humans, it must have an extremely broad dialog within the critical scientific public and the general public, which are represented on committees functioning in the Bureau of Biologics. There must be a generaly consensus regarding the benefit/risk ratio of proposed new biologicals for scientific progress and the effective regulation of biologicals.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Limite:
Humans
País/Região como assunto:
America do norte
Idioma:
En
Revista:
Cancer Res
Ano de publicação:
1976
Tipo de documento:
Article